Dekker AW - Search Results

1

Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma.

Ahsmann EJ, Lokhorst HM, Dekker AW, Bloem AC. Ahsmann EJ, et al. Among authors: dekker aw. Blood. 1992 Apr 15;79(8):2068-75. Blood. 1992. PMID: 1562732 Free article.

2

Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft.

Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK. Verdonck LF, et al. Among authors: dekker aw. Blood. 1994 May 15;83(10):3090-6. Blood. 1994. PMID: 8180405 Free article.

3

Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.

Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Verdonck LF, et al. Among authors: dekker aw. Blood. 1997 Nov 15;90(10):4201-5. Blood. 1997. PMID: 9354692 Free article.

4

Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.

Raaijmakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P. Raaijmakers HG, et al. Among authors: dekker aw. Blood. 1998 Feb 1;91(3):1029-36. Blood. 1998. PMID: 9446666 Free article.

5

J chain disease: an aggressive evolution of multiple myeloma.

Lokhorst HM, Dekker AW, Baarlen JV, Bast EJ. Lokhorst HM, et al. Among authors: dekker aw. Am J Med. 1990 Apr;88(4):417-20. doi: 10.1016/0002-9343(90)90500-d. Am J Med. 1990. PMID: 2109533 No abstract available.

6

Advances in the treatment of multiple myeloma.

Lokhorst HM, Dekker AW. Lokhorst HM, et al. Among authors: dekker aw. Cancer Treat Rev. 1993 Apr;19(2):113-28. doi: 10.1016/0305-7372(93)90030-u. Cancer Treat Rev. 1993. PMID: 7683253 Review. No abstract available.

7

Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.

Terpstra WE, Lokhorst HM, Blomjous F, Meuwissen OJ, Dekker AW. Terpstra WE, et al. Among authors: dekker aw. Br J Haematol. 1992 Sep;82(1):46-9. doi: 10.1111/j.1365-2141.1992.tb04592.x. Br J Haematol. 1992. PMID: 1419801

8

Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.

Lokhorst HM, Sonneveld P, Wijermans PW, van Marwijk Kooy M, Meuwissen OJ, van Oers RH, van der Griend R, Dekker AW. Lokhorst HM, et al. Among authors: dekker aw. Br J Haematol. 1996 Jan;92(1):44-8. doi: 10.1046/j.1365-2141.1996.00306.x. Br J Haematol. 1996. PMID: 8562409 Clinical Trial.

9

Graft-versus-myeloma effect in two cases.

Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Verdonck LF, et al. Among authors: dekker aw. Lancet. 1996 Mar 23;347(9004):800-1. doi: 10.1016/s0140-6736(96)90871-5. Lancet. 1996. PMID: 8622337

10

Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.

Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG, de Weger RA. Verdonck LF, et al. Among authors: dekker aw. Bone Marrow Transplant. 1998 Dec;22(11):1057-63. doi: 10.1038/sj.bmt.1701496. Bone Marrow Transplant. 1998. PMID: 9877267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page